Last update 19 Nov 2024
BGB-B2033
Last update 19 Nov 2024
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms GPC3 x 4-1BB BsAb (BeiGene), BGB B2033, BGB-B2033 + [1] |
Target |
Mechanism 4-1BB modulators(Tumor necrosis factor receptor superfamily member 9 modulators), GPC3 inhibitors(Glypican-3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with BGB-B2033一项探索BGB-B2033单药治疗以及与替雷利珠单抗联合治疗在选定的晚期或转移性实体瘤受试者中的安全性、耐受性、药代动力学、药效学和初步抗肿瘤活性的1期研究（目前仅开展单药试验）
[Translation] A Phase 1 study exploring the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BGB-B2033 as monotherapy and in combination with tislelizumab in selected subjects with advanced or metastatic solid tumors (currently only monotherapy trials are being conducted)
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
100 Clinical Results associated with BGB-B2033
Login to view more data
100 Translational Medicine associated with BGB-B2033
Login to view more data
100 Patents (Medical) associated with BGB-B2033
Login to view more data
100 Deals associated with BGB-B2033
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced Hepatocellular Carcinoma | Phase 1 | US | 23 Jul 2024 | |
| Advanced Hepatocellular Carcinoma | Phase 1 | CN | 23 Jul 2024 | |
| Advanced Hepatocellular Carcinoma | Phase 1 | NZ | 23 Jul 2024 | |
| Endodermal Sinus Tumor | Phase 1 | US | 23 Jul 2024 | |
| Endodermal Sinus Tumor | Phase 1 | CN | 23 Jul 2024 | |
| Endodermal Sinus Tumor | Phase 1 | NZ | 23 Jul 2024 | |
| Endodermal Sinus Tumor | Phase 1 | KR | 23 Jul 2024 | |
| Hepatocellular Carcinoma | Phase 1 | US | 23 Jul 2024 | |
| Hepatocellular Carcinoma | Phase 1 | NZ | 23 Jul 2024 | |
| Hepatocellular Carcinoma | Phase 1 | KR | 23 Jul 2024 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free